Venture Partner at Catalio Capital Management
View Live Interactive Profile →Catalio Capital Management lists Keith T. Flaherty as a Venture Partner. The firm's profile page gives the current affiliation as Director of Clinical Research and Richard Saltonstall Chair in Oncology at the MGH Cancer Center; Professor of Medicine, Harvard Medical School. His stated honours include the NCI CTEP Michaele Christian Oncology Development Award and Lectureship (2015), membership of the NCI Board of Scientific Advisors (2018, chair from 2021), the AACR Board of Directors (2018) and the Society for Melanoma Research Lifetime Achievement Award (2019). Catalio's page lists him as a co-founder of Loxo Oncology, Strata Oncology, X4 Pharmaceuticals, Apricity, C-Reveal and Scorpion Therapeutics and names directorships at Loxo Oncology, Scorpion Therapeutics, Strata Oncology, Checkmate Pharmaceuticals, Clovis Oncology and Kinnate Biopharma; several of those companies have since been acquired and none were confirmed as current, so they are not recorded as board seats.